EchoTip AcuCore Post-Market Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Shelley Farrester
- Phone Number: 765-463-7537
- Email: shelley.farrester@cookmedical.com
Study Locations
-
-
California
-
Orange, California, United States, 92868
- University of California, Irvine
-
-
Colorado
-
Denver, Colorado, United States, 80210
- Advent Health, Porter
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida Shands Hospital
-
Gainesville, Florida, United States, 32610
- Shands Hospital-University of Florida
-
Orlando, Florida, United States, 32803
- Advent Health Medical Group, Orlando
-
-
Pennsylvania
-
Danville, Pennsylvania, United States, 17822
- Geisinger Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Memorial Hermann Hospital
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient has been referred for an endoscopic ultrasound (EUS) fine needle biopsy procedure
- The EchoTip AcuCore device is the first EUS biopsy needle used in the procedure.
Exclusion Criteria:
- Patient's age is less than 18 years
- Patient is unable or unwilling to sign and date the informed consent. If IRB approves a waiver of consent, this exclusion criterion is not applicable.
- Patient is simultaneously participating in another pre-market investigational drug or pre-market investigational device study involving an EUS fine needle biopsy procedure and for which the patient has not completed the follow-up phase for the primary endpoint at least 30 days prior to enrollment in this study.
- Inaccessible or unsuitable lesion (lesion not visualized or a large vessel, duct or primary mass interposition)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EchoTip AcuCore
Patients with use of AcuCore 22 gauge FNB to collect specimens from GI tract
|
Using endoscopic ultrasound guided needle to collect biopsies
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Technical Success
Time Frame: Duration of the procedure (approx. 1 hr)
|
The ability to obtain a sample without failure of the needle system necessitating the use of a new needle to complete the procedure
|
Duration of the procedure (approx. 1 hr)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Pancreatic Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Liver Neoplasms
- Neoplastic Processes
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Carcinoma
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Pancreatitis
- Autoimmune Pancreatitis
- Carcinoma, Hepatocellular
- Lymphoma
- Neoplasm Metastasis
- Pancreatitis, Chronic
- Cholangiocarcinoma
- Adenocarcinoma
- Neuroendocrine Tumors
Other Study ID Numbers
Other Study ID Numbers
- 21-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.